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Introduction
Radical prostatectomy has been a standard treatment for
clinical localized prostate cancer for more than a decade1
with excellent results.2–5 Since the incidence of prostate
cancer in Asia is lower than in Western countries,6 most
data in the literature are from the West, although some are
from East Asia.7 To our knowledge, few data on radical
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prostatectomy have been published on Asian men in the
Southeast Asia region including Thailand. At present, not
only the incidence but also early stage prostate cancer is
increasing in Thailand.8 For patients with early stage pros-
tate cancer, radical prostatectomy has become the pre-
ferred therapy. To determine the outcomes of radical prosta-
tectomy in Thailand, this retrospective descriptive study was
done.
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OBJECTIVE: Radical prostatectomy remains the standard treatment for early prostate cancer. Few data in the
literature are from South East Asia. This study was conducted to evaluate the outcome of radical prostatectomy
in Thai men.
METHODS: A total of 151 patients with prostate cancer underwent radical prostatectomy at Siriraj Hospital,
Bangkok, between 1994 and 2003. Clinical staging, preoperative prostate-specific antigen (PSA) and Gleason
score were evaluated with pathological stage and margin status. Follow-up PSA monitoring and survival were
analysed.
RESULTS: Of 121 patients with clinical localized disease, 79 (65.3%), 40 (33.1%) and two (1.6%) had localized,
locally advanced and metastatic disease, respectively, on pathology. The chance of localized disease with a
preoperative PSA of 10 ng/mL or less, more than 10–50 ng/mL and more than 50 ng/mL was 75.5%, 50% and
12.5%, respectively (all p < 0.001). The chance of localized disease with a Gleason score of 2–4, 5–7 and 8–10 was
85%, 55.1% and 20.8%, respectively (all p < 0.02). Mean follow-up was 30 months. Among 140 evaluable patients,
51 (36.4%) had adjuvant therapy and 136 (97.1%) had undetectable PSA without clinical progression. The
cumulative PSA progression-free survival among patients with pathological T1N0, T2N0 and T3N0 disease was
0.83 at 82 months, 0.48 at 85 months and 0.31 at 57 months, respectively.
CONCLUSION: Radical prostatectomy in Thai men shows excellent results. The trend is the same as in Western
series. The chance of organ-confined disease and free margin was high in patients with clinical T2 or less, PSA less
than 10 ng/mL and low Gleason score. PSA progression-free survival was high in patients with organ-confined
disease. [Asian J Surg 2005;28(4):286–90]
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Patients and methods
Between 1994 and 2003, 151 patients with prostate cancer
underwent radical prostatectomy at Siriraj Hospital, Bangkok.
A computerized database was established. The data for all
patients were reviewed from both inpatient records for surgery
and outpatient records for follow-up results. Only seven un-
derwent radical prostatectomy during 1994–1998, but from
1999 to May 2003, radical prostatectomy was performed in
144 patients. All prostate cancers were adenocarcinoma graded
using Gleason score. Of 151 patients, 128 (84.8%) patients
were diagnosed by transrectal ultrasound (TRUS)-guided
biopsy. Abnormal prostate-specific antigen (PSA; > 4 ng/mL)
and abnormal digital rectal examination (DRE) were criteria
for prostatic biopsy. Twenty-three patients (15.2%) were diag-
nosed from incidental findings at transurethral resection of
the prostate (TURP). The 1997 TNM classification was used
for staging.9 All patients had a negative bone scan. Therapeu-
tic options were discussed between patients and physicians
including a urologist, radiotherapist or oncologist. A total of
148 patients underwent retropubic radical prostatectomy. If a
patient had low-risk prostate cancer, bilateral nerve sparing
radical prostatectomy was performed. Three patients under-
went laparoscopic radical prostatectomy, two of whom were
converted to retropubic radical prostatectomy. After radical
prostatectomy, PSA was monitored during follow-up. If PSA
was rising, clinical status was evaluated. Adjuvant therapy was
used for biochemical failure or clinical progression. Mean
follow-up in our series was 30 months (median, 27 months;
range, 10–85 months). Eleven patients were lost to follow-up
and 140 patients were evaluated for follow-up. Patient charac-
teristics were evaluated. Preoperative PSA, tumour grade and
clinical stage were analysed according to pathological stage
and margin status. Cancer control was evaluated in terms of
last PSA status, PSA progression-free survival, biochemical
failure, clinical progression and cancer-specific survival. SPSS
(SPSS Inc, Chicago, IL, USA) was used for analysis, with Chi-
squared test to compare categorical variables and Kaplan-
Meier to calculate survival.
Results
Mean age was 66.2 years (range, 51–82 years). Only one patient
was more than 80 years old. The mean and median of pre-
operative PSA were 27.3 and 16 ng/mL, respectively (range,
1.2–225 ng/mL). Table 1 shows the distribution of symptoms
and signs, preoperative PSA, tumour grade and clinical T
stage. Of the 151 patients, 81 (53.6%), 62 (41.1%) and eight
(5.3%) had pathological localized, locally advanced and meta-
static disease, respectively. Of 121 patients with clinical local-
ized disease, 79 (65.3%), 40 (33.1%) and two (1.6%) had patho-
logical localized, locally advanced and metastatic disease,
respectively. On the other hand, of 30 patients with clinical T3
disease, two (6.7%), 22 (73.3%) and six (20%) had pathological
localized, locally advanced and metastatic disease, respectively.
Table 2 shows the correlation between preoperative PSA and
pathological stage. The chance of localized disease was 75.5%,
50% and 12.5% at a preoperative PSA of 10 or less, more than
Table 1. Distribution of symptoms and signs, preoperative prostate-
specific antigen (PSA), tumour grade (Gleason score) and clinical
T stage
n (%)0
Symptoms and signs
   No symptoms 39 (25.8)
   Lower urinary tract symptoms 106 (70.2)0
   Urinary retention 4 (2.6)
   Haematuria 2 (1.3)
Preoperative PSA (ng/mL)
   0–4 8 (5.3)
   > 4–10 37 (24.5)
   > 10–20 43 (28.5)
   > 20–50 37 (24.5)
   > 50 18 (11.9)
   Missing 8 (5.3)
Gleason score
   2–4 20 (13.2)
   5–7 107 (70.9)0
   8–10 24 (15.9)
Clinical T stage
   T1 58 (38.4)
   T2 63 (41.7)
   T3 30 (19.9)
Table 2. Correlation of preoperative prostate-specific antigen
(PSA) and pathological stage
Preoperative Pathological stage, n
PSA (ng/mL) Localized Locally advanced Metastasis
) 10 34 11 0
> 10–20 20 21 2
> 20–50 20 13 4
> 50 02 15 1
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10–50 and more than 50 ng/mL, respectively (all p < 0.001).
These data suggest that lower preoperative PSA indicates a
higher chance of localized disease. Table 3 shows the correla-
tion between Gleason score and pathological stage. The chance
of localized disease in patients with a Gleason score of 2–4, 5–
7 or 8–10 was 85%, 55.1% or 20.8%, respectively (all p < 0.02).
Table 4 shows the correlation of pathological stage with mar-
gin status. Of 81 patients with pathological localized disease,
75 (92.6%) had free margin, significantly more than the 21 of
62 patients (33.9%) with pathological locally advanced disease
(p < 0.001).
Eleven patients were lost to follow-up. Of the remaining
140, 75 (53.6%), 58 (41.4%) and seven (5%) had pathological
localized, locally advanced and metastatic disease, respective-
ly. Within 1 month after surgery, PSA level decreased to an
undetectable level (< 0.2 ng/mL). It is our hospital policy that
immediate adjuvant therapy be used if patients have meta-
static disease, locally advanced disease with a positive margin
or no decline of PSA to an undetectable level. Several adjuvant
therapies are used, including radiation, hormonal therapy and
combined treatments. Decisions are made after discussion
between patients and physicians. Of 140 patients, 27 with
pathological locally advanced disease and all seven with patho-
logical metastatic disease had immediate adjuvant therapy.
Increasing PSA after radical prostatectomy is defined as bio-
chemical failure. Over the mean follow-up of 30 months and
longest follow-up of 85 months, seven patients with patho-
logical localized disease and 10 with pathological locally ad-
vanced disease had increasing PSA and received adjuvant
therapy. Thus, 51 patients (36.3%) had adjuvant therapy in our
series. Most had pathological locally advanced or metastatic
disease. Of 75 patients with pathological localized disease,
only seven (9.3%) had adjuvant therapy, significantly lower
than the 37 patients (63.7%) with pathological locally ad-
vanced disease (p < 0.001). Of 51 patients receiving adjuvant
therapy, 39 had bilateral orchiectomy, four had luteinizing
hormone-releasing hormone agonist, five had external beam
radiation and three had combination therapy with bilateral
orchiectomy and external beam radiation. The Figure shows
PSA progression-free survival stratified by pathological T1N0,
T2N0 and T3N0 disease. Cumulative PSA progression-free
survival with pathological T1N0, T2N0 and T3N0 disease was
0.83 at 82 months, 0.48 at 85 months and 0.31 at 57 months,
respectively. Patients with T3 disease tended to have biochemi-
cal failure more than patients with T1 or T2 disease. However,
the log rank test showed that PSA progression-free survival
was not significantly different (p = 0.804) because follow-up
was not long enough. At a mean follow-up of 30 months, the
cumulative survival curves for each T stage were close to each
other. These graphs tended to separate at 60 months’ follow-
up. Adjuvant therapy after radical prostatectomy showed ex-
cellent results in terms of PSA level and clinical status. In
almost all patients, PSA decreased to an undetectable level. At
the time of analysis, overall results of radical prostatectomy in
this series were satisfactory. Of 140 patients, 136 (97.1%) had
PSA less than 0.2 ng/mL and no clinical progression. Three
patients had increasing PSA without clinical progression.
However, one patient died from metastatic prostate cancer. He
had T3N0M0 and a Gleason score of 8 at the time of diagnosis.
Twelve patients had morbidity: five had significant bleed-
ing () 2,000 mL), three had wound infection, two had pro-
longed lymphatic leakage, one had prolonged urinary leakage
and one had scrotal haematoma. All patients with significant
bleeding underwent radical prostatectomy early in our
experience. Bleeding decreased considerably as we gained
experience. There was no mortality in our series. Postoperative
incontinence was acceptable: seven patients had mild stress
incontinence and two had significant incontinence requiring
a diaper. However, eight patients had anastomotic stricture,
Table 3. Correlation of Gleason score and pathological stage
Gleason Pathological stage, n
score Localized Locally advanced Metastasis
2–4 17 02 1
5–7 59 44 4
8–10 05 16 3
Table 4. Correlation of pathological stage and margin status
Pathological stage Free margin, n (%) Positive margin, n (%) Total, n (%)
Localized 75 (92.6) 6 (7.4) 81 (100)
Locally advanced 21 (33.9) 41 (66.1) 62 (100)
Metastasis 01 (12.5) 07 (87.5) 08 (100)
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all of which were managed with dilatation. Potency after
radical prostatectomy was difficult to evaluate in our series.
Many patients were impotent before surgery. Bilateral nerve-
sparing radical prostatectomy was used in selected patients
who had a low PSA and low Gleason score. Some patients still
had potency after bilateral nerve-sparing radical prostatectomy.
Discussion
Since there has been more awareness of prostate cancer among
Thai men in Bangkok, our hospital has had more patients
diagnosed with prostate cancer. More clinical localized disease
has been detected, resulting in more radical prostatectomy. Of
patients with early prostate cancer, most presented with high
PSA (10–20 ng/mL), lower urinary tract symptoms, a Gleason
score of 5–7 and clinical T1 or T2 disease. Since mean age was
more than 60 years, most patients had coincident benign
prostatic hyperplasia (BPH). Some patients who presented
with BPH urinary retention had incidental diagnosis of pros-
tate cancer at TURP at another institution and were referred to
our hospital for definitive treatment.
Many studies show that men with clinical localized pros-
tate cancer treated with radical prostatectomy might have
localized, locally advanced or metastatic disease on pathology.
The important factors indicating organ-confined disease are
preoperative PSA, Gleason score and clinical T stage.2–5 Our
series in Thai men showed the same trends. Preoperative PSA
level, Gleason score and clinical T stage were significantly
different with pathological stage of disease. Our data sug-
gested that the possibility of organ-confined disease is high
when patients have a preoperative PSA level of 10 ng/mL or
less, low Gleason Score and clinical T1 or T2 disease. In
addition, the possibility of a free surgical resection margin was
more than 90% if patients had organ-confined disease. On the
other hand, patients at high risk such as those with a high
preoperative PSA, high Gleason score or clinical T3 disease
mostly had pathological locally advanced or metastatic disease,
and a positive margin was common in these patients.
Even though the follow-up in our series was not as long
as in series in Western countries, the trend in survival param-
eters seemed to be the same as in those series. Radical pros-
tatectomy showed excellent results in terms of PSA, PSA
progression-free survival and cancer-specific survival. At a
mean follow-up of 30 months, 97% of patients had undetect-
able PSA without clinical progression. Only one patient died
of metastatic prostate cancer. PSA progression-free survi-
val in the patients with localized disease tended to be higher
than that in patients with locally advanced disease. However,
it was not statistically different because of the short follow-up.
In patients with biochemical failure, adjuvant radiotherapy or
adjuvant hormonal therapy was used, decreasing PSA to an
undetectable level in most patients.
The incidence of prostate cancer varies among different
races. Prostate cancer is much less common in Asian men than
in Western men.6 However, radical prostatectomy has gained
popularity in Asia, as reported from Japan.7 Our data also
showed an increase in this procedure in Thailand. Despite
differences in incidence among races, the natural history or
disease progression seems to be the same. The important
prognostic factors are Gleason score, preoperative PSA and
clinical T stage. Thai men with low PSA, low clinical T stage
and low Gleason score are likely to have organ-confined dis-
ease and a low risk of biochemical failure, as also shown in
series from Japan and Western countries.2–5,7 We believe that
our data provide information for decision-making for Thai or
Asian men with clinical localized prostate cancer.
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Figure. Prostate-specific antigen (PSA) progression-free survival
stratified by pathological T stage (all no metastasis).
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